Financials

News Ideas Minds Technicals

4114 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to SYNMOSA BIOPHARMA CORP operating, investing, and financing activities

4114 free cash flow for Q1 24 is 44.88 M TWD. For 2023, 4114 free cash flow was 262.31 M TWD and operating cash flow was 469.36 M TWD.

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: TWD

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

TTM

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—